gefitinib has been researched along with curcumin in 5 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (curcumin) | Trials (curcumin) | Recent Studies (post-2010) (curcumin) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 16,336 | 593 | 12,705 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
Authors | Studies |
---|---|
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Chang, GC; Chen, HW; Chen, JJ; Hsieh, WY; Lee, JY; Lee, YM; Yang, PC; Yu, SL | 1 |
Chen, CG; Chen, K; Chen, P; Huang, HP; Jin, J; Li, J; Long, WG; Wang, Y; Zhao, XH | 1 |
Cheng, ZY; Chueh, FS; Chung, JG; Hsiao, YT; Lai, KC; Lien, JC; Liu, KC; Peng, SF | 1 |
Chen, HM; Chen, HY; Chiang, CP; Li, WC; Lin, HY; Wei, YC; Yang, H | 1 |
1 review(s) available for gefitinib and curcumin
Article | Year |
---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
4 other study(ies) available for gefitinib and curcumin
Article | Year |
---|---|
Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Intestinal Mucosa; Intestines; Lung Neoplasms; Mice; Mice, SCID; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Ubiquitination; Xenograft Model Antitumor Assays | 2011 |
Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Curcumin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mutation; Protein Binding; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2019 |
Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Curcumin; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Nanoparticles; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2019 |
Natural Compounds Modulate Drug Transporter Mediated Oral Cancer Treatment.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Catechin; Cell Line, Tumor; Cell Survival; Curcumin; Gefitinib; Humans; Kaplan-Meier Estimate; Mouth Neoplasms; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents | 2020 |